These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21348837)

  • 1. Aggregation state and neurotoxic properties of alzheimer β-amyloid peptide.
    Mohamed A; Cortez L; de Chaves EP
    Curr Protein Pept Sci; 2011 May; 12(3):235-57. PubMed ID: 21348837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The heterogeneous nature of Cu2+ interactions with Alzheimer's amyloid-β peptide.
    Drew SC; Barnham KJ
    Acc Chem Res; 2011 Nov; 44(11):1146-55. PubMed ID: 21714485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
    Matsuzaki K
    Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.
    Nyakas C; Granic I; Halmy LG; Banerjee P; Luiten PG
    Behav Brain Res; 2011 Aug; 221(2):594-603. PubMed ID: 20553766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease.
    Standridge JB
    Curr Alzheimer Res; 2006 Apr; 3(2):95-108. PubMed ID: 16611010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
    Tomiyama T
    Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
    Brody DL; Jiang H; Wildburger N; Esparza TJ
    Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-amyloid, neuronal death and Alzheimer's disease.
    Carter J; Lippa CF
    Curr Mol Med; 2001 Dec; 1(6):733-7. PubMed ID: 11899259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.
    Thal DR; Walter J; Saido TC; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):167-82. PubMed ID: 25534025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation.
    Bokvist M; Lindström F; Watts A; Gröbner G
    J Mol Biol; 2004 Jan; 335(4):1039-49. PubMed ID: 14698298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease.
    Rajasekhar K; Chakrabarti M; Govindaraju T
    Chem Commun (Camb); 2015 Sep; 51(70):13434-50. PubMed ID: 26247608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptides as Potential Therapeutics for Alzheimer's Disease.
    Ribarič S
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"].
    Tamaoka A
    Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
    Watson D; Castaño E; Kokjohn TA; Kuo YM; Lyubchenko Y; Pinsky D; Connolly ES; Esh C; Luehrs DC; Stine WB; Rowse LM; Emmerling MR; Roher AE
    Neurol Res; 2005 Dec; 27(8):869-81. PubMed ID: 16354549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.
    Jan A; Hartley DM; Lashuel HA
    Nat Protoc; 2010 Jun; 5(6):1186-209. PubMed ID: 20539293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization.
    De Felice FG; Vieira MN; Saraiva LM; Figueroa-Villar JD; Garcia-Abreu J; Liu R; Chang L; Klein WL; Ferreira ST
    FASEB J; 2004 Sep; 18(12):1366-72. PubMed ID: 15333579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry.
    Carlred L; Michno W; Kaya I; Sjövall P; Syvänen S; Hanrieder J
    J Neurochem; 2016 Aug; 138(3):469-78. PubMed ID: 27115712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.
    Kar S; Slowikowski SP; Westaway D; Mount HT
    J Psychiatry Neurosci; 2004 Nov; 29(6):427-41. PubMed ID: 15644984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.